Breaking Finance News

Joh. Berenberg Gossler & Co. KG announced RHOEN-KLINIKUM (ETR:RHK), bumping its price target to 28.00EUR earlier today

Stating as potential upside of 0.03%, Joh. Berenberg Gossler & Co. KG upped the price target of RHOEN-KLINIKUM (ETR:RHK) to 28.00EUR

On 9/20/2016, Commerzbank AG released a statement on RHOEN-KLINIKUM (ETR:RHK) upped the target price from 0.00EUR to 31.00EUR that suggested an upside of 0.13%.

Having a price of 27.26EUR, RHOEN-KLINIKUM (ETR:RHK) traded 0.00% even on the day. With the last close up 0.00% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. RHOEN-KLINIKUM has recorded a 50-day average of 0.00EUR and a two hundred day average of 0.00EUR. Volume of trade held steady, with 0 shares of RHK changing hands on par with the typical 0

Performance Chart


With a total market value of 0 EUR, RHOEN-KLINIKUM has with a one year low of 0.00EUR and a one year high of 0.00EUR .


Rhoen Klinikum AG is a Germany-based provider of health care services. It is primarily engaged in building, acquiring and operating privately owned hospitals. The Company's portfolio comprises basic and standard care, intermediate care, maximum care, specialist care, medical care centers (MVZ) at hospitals, portal clinics, university hospitals and academic teaching hospitals. These hospitals offer treatment in several specialist fields, including psychiatry, anesthesiology, dermatology, ophthalmology, various types of surgery, women's medicine and obstetrics, geriatrics, neurology, rehabilitation, urology and internal medicine, among others. The Company operated a number of hospitals and medical care centers. In addition to the hospitals in Bad Berka, Frankfurt, Hildesheim, Karlsruhe, Munich, Pforzheim and Wiesbaden, among others, it has MVZ companies located in Germany, as well as two research and education companies and service companies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.